Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Cancer × Sorafenib × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 69 Carcinoma, Renal Cell 31 Neoplasms 28 Liver Neoplasms 19 Carcinoma 6 Thyroid Neoplasms 4 Neoplasm Metastasis 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Breast Neoplasms 3 Vaccinia 1 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Liver Diseases 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Kidney Neoplasms 1 Insulin-Like Growth Factor I, Resistance To 1 Hypophosphatemia 1 Hepatitis C 1 Hepatitis B 1 Glioblastoma 1 Digestive System Neoplasms 1 Digestive System Diseases 1 Colorectal Neoplasms 1 Carcinoma, Medullary 1 COVID-19 1

Interventions

Nivolumab 13 linrodostat 5 Ipilimumab 5 relatlimab 3 Pemetrexed 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 regorafenib 2 abemaciclib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Gemcitabine 2 Capecitabine 2 ARRY-334543 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 trametinib 1 tislelizumab 1 sargramostim 1 ralimetinib 1 palifosfamide lysine 1 p38 Mitogen-Activated Protein Kinases 1 lirilumab 1 fluzoparib 1 fluorapacin 1 etirinotecan pegol 1 emibetuzumab 1 efatutazone 1 cemiplimab 1 bempegaldesleukin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00785226 2016-10-17

RDEA119 and Sorafenib Combination Dose Escalation Study

Bayer

Phase 1/2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡